Bayer's innovative cell therapy and gene therapy for the treatment of Parkinson's disease enter clinical trials

On June 8, 2021, Bayer announced that its BlueRock Therapeutics (BlueRock) company had successfully transplanted DA01, a dopaminergic neuron therapy produced by pluripotent stem cells, to a Parkinson’s disease in a phase 1 clinical trial.

Parkinson's disease is the most common neurodegenerative movement disorder, affecting more than 10 million people worldwide

Using real dopaminergic neurons, BlueRock aims to re-establish the innervation of the affected areas of the human brain, thereby reversing the degeneration process and potentially restoring the patient's motor function

AskBio's gene therapy uses AAV vectors to deliver genes encoding human glial cell-derived neurotrophic factor (GDNF) to neurons in the putamen, resulting in the expression and secretion of GDNF protein in brain regions affected by Parkinson's disease

Note: The original text has been deleted

Reference materials:

[1] Bayer to advance two first-of-its-kind cell and gene therapies for Parkinson's disease.